[go: up one dir, main page]

AR027513A1 - PHARMACEUTICAL PREPARATION - Google Patents

PHARMACEUTICAL PREPARATION

Info

Publication number
AR027513A1
AR027513A1 ARP010100136A ARP010100136A AR027513A1 AR 027513 A1 AR027513 A1 AR 027513A1 AR P010100136 A ARP010100136 A AR P010100136A AR P010100136 A ARP010100136 A AR P010100136A AR 027513 A1 AR027513 A1 AR 027513A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical preparation
thieno
benzylamino
pyrimidin
benzo
Prior art date
Application number
ARP010100136A
Other languages
Spanish (es)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR027513A1 publication Critical patent/AR027513A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente se relaciona con una preparacion farmacéutica que contiene por lo menos ácido 4-[4-(3-cloro-4-metoxi-bencilamino)-benzo[4,5]tieno[2,3-d]pirimidin-2-il]-ciclo-hexancarboxílico o una de sus sales farmacéuticamente inofensivas y/o ácido 4-[4 -(3-cloro-4-hidroxi-bencilamino)-benzo[4,5]tieno[2,3-d]pirimidin-2-il]-ciclohexancarboxílico o una de sus sales farmacéuticamente inofensivas, un material portados, un agente explosivo y eventualmente un agenteregulador del flujo.This is related to a pharmaceutical preparation containing at least 4- [4- (3-chloro-4-methoxy-benzylamino) -benzo [4,5] thieno [2,3-d] pyrimidin-2-yl acid ] -cyclohexylcarboxylic or one of its pharmaceutically harmless salts and / or 4- [4 - (3-Chloro-4-hydroxy-benzylamino) -benzo [4,5] thieno [2,3-d] pyrimidin-2 acid -yl] -cyclohexanecarboxylic or one of its pharmaceutically harmless salts, a ported material, an explosive agent and possibly a flow regulating agent.

ARP010100136A 2000-01-13 2001-01-12 PHARMACEUTICAL PREPARATION AR027513A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2000101021 DE10001021A1 (en) 2000-01-13 2000-01-13 Pharmaceutical preparation

Publications (1)

Publication Number Publication Date
AR027513A1 true AR027513A1 (en) 2003-04-02

Family

ID=7627303

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100136A AR027513A1 (en) 2000-01-13 2001-01-12 PHARMACEUTICAL PREPARATION

Country Status (4)

Country Link
AR (1) AR027513A1 (en)
AU (1) AU2001231663A1 (en)
DE (1) DE10001021A1 (en)
WO (1) WO2001051052A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10107261B4 (en) * 2001-02-16 2005-03-10 Merck Patent Gmbh Pharmaceutical composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31122A (en) * 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
DE19644228A1 (en) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidines
DE19819023A1 (en) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidines
DE19928146A1 (en) * 1999-06-19 2000-12-21 Merck Patent Gmbh New 3-benzylamino-benzothienopyrimidine derivatives inhibit phosphodiesterase V and are useful for treating cardiac insufficiency and impotence

Also Published As

Publication number Publication date
AU2001231663A1 (en) 2001-07-24
DE10001021A1 (en) 2001-07-19
WO2001051052A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
BR9913626A (en) Ranolazine formulations for continuous release
BR0109091A (en) Sustained Release Ranolazine Formulations
CR6656A (en) DOSAGE FORM OF DRUGS DRIVEN BY A HYDROGEL
UY27175A1 (en) NEW SUCCINATE SALT OF O-DESMETIL- VENLAFAXINA
CL2008002407A1 (en) Oral dosage form comprising at least one nicotine active agent, at least one bioadhesive material capable of forming a hydrogen bond with the nicotine active agent, and at least one rapidly releasing sensory impact agent; and its use to provide rapid relief from nicotine cravings (div. sol. 1825-04).
BRPI0313148B8 (en) solid matrix formulations of lamotrigine containing outer coating and perforation in such coating
ES2111547T3 (en) PROLONGED RELEASE TABLET.
UY26131A1 (en) PHARMACEUTICAL COMPOSITION IN UNITARY FORM CONTAINING CLOPIDOGREL HYDROGENOSULPHATE AND ACETYLSALICYL ACID.
BR0000195A (en) Direct-acting antimycotic
ATE291914T1 (en) MEDICINAL COMPOSITIONS CONTAINING ZOLEMTRIPT
DK1112060T3 (en) Dosage form using liquid formulation
ATE482683T1 (en) ABSORBENT ITEM WITH IMPROVED FIT
ES2164310T3 (en) MARRIAGE TABLETS FOR ORAL USE AND LONG-TERM RELEASE CONTAINING THE SODIUM SALT OF TIANEPTINE.
PE20030696A1 (en) BRIVUDINE, STABILIZED IN TOPICAL FORMULATIONS
MY136059A (en) Swallow tablet comprising paracetamol
IS6654A (en) Stable gabapentin with pH within the controlled range
AR027513A1 (en) PHARMACEUTICAL PREPARATION
ATE70445T1 (en) PHARMACEUTICAL PREPARATIONS.
SE0001916D0 (en) Novel formulation
BR0210632A (en) Parasitic disease treatment
CO6341549A2 (en) COMBINATION COCCIDICIDE FOR VETERINARY USE
ES2092559T3 (en) PHARMACEUTICAL FORMULATION CONTAINING PENCICLOVIR.
AR032695A1 (en) PHARMACEUTICAL COMPOSITION
CO5640085A2 (en) PHARMACEUTICAL FORMULATIONS THAT INCLUDE AMOXYCLINE AND CLAVULANATE
TW200509990A (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
FB Suspension of granting procedure